Cambridge, Mass. – March 22, 2018 – Shire plc (LSE: SHP, NASDAQ: SHPG) today announced the release of the Company’s 2017 Annual Responsibility Review. The Review, available at shire.com/responsibility, outlines Shire’s new Responsibility strategy that includes ambitious long-term goals to be achieved by 2025, aimed at further enhancing the Company’s commitment to Responsibility and positively impacting patients, our employees, and our communities.
“Shire's enterprise-wide commitment to Responsibility is integral to our mission to serve the needs of patients and those who care for them,” said Flemming Ornskov, M.D., M.P.H., Shire’s Chief Executive Officer. “Our new Responsibility strategy was created to have a strong positive impact on our business and society – from serving patients, to supporting our communities, to protecting our environment.”
Shire has long been recognized for our commitment to Responsibility, including being listed on the FTSE4Good Index Series for positive environmental, social and governance practices since 2001. Shire’s Responsibility strategy lays out nine commitments that will enable the Company to do even more for patients, employees, and the global community. These commitments are aligned to three strategic Responsibility pillars: Supporting patients, People and culture, and Sustainable operations. The Annual Responsibility Review details the strategy’s commitments and goals, summarized as:
Additional information about Responsibility at Shire can also be found in Shire’s 2017 Annual Report, available at http://investors.shire.com/presentations-and-reports/ar-2017.aspx
For more information, please visit http://www.shire.com. Follow Shire on Social Media: Twitter, LinkedIn and YouTube.
|Christoph Brackmannemail@example.com||+41 795 432 359|
|Sun Kimfirstname.lastname@example.org||+1 617 588 8175|
|Robert Coatesemail@example.com||+44 203 549 0874|
|Katie Joycefirstname.lastname@example.org||+1 781 482 2779|
|Elaine Salewskeemail@example.com||+1 847 323 8134|
Shire is the global leader in serving patients with rare diseases. We strive to develop best-in-class therapies across a core of rare disease areas including hematology, immunology, genetic diseases, neuroscience, and internal medicine with growing therapeutic areas in ophthalmics and oncology. Our diversified capabilities enable us to reach patients in more than 100 countries who are struggling to live their lives to the fullest.
We feel a strong sense of urgency to address unmet medical needs and work tirelessly to improve people’s lives with medicines that have a meaningful impact on patients and all who support them on their journey.